SVA (SVA) revenue breakdown
By product, Enterovirus 71 vaccines is the largest at 61% of fiscal 2019 revenue; Mumps Vaccines grew fastest, 246% a year over 3 years.
By region, PRC is the largest at 68% of fiscal 2025 revenue; Outside Chinese Mainland grew fastest, 67% a year over 9 years.
Revenue by product
Fiscal years, as SVA reports them in its 10-K filings; fiscal 2019 total $246M.
| Products | 2016 | 2017 | 2018 | 2019 | Share |
|---|---|---|---|---|---|
| Enterovirus 71 vaccines | $35M | $121M | $163M | $149M | 61% |
| Inactivated hepatitis vaccines | $21M | $38M | $63M | $58M | 24% |
| Mumps Vaccines | $477,000 | $2M | $2M | $20M | 8% |
| Influenza vaccines | $10M | $14M | $2M | $19M | 8% |
| Grants For H5N1 2013 Vaccines | $6M | — | — | — | — |
Revenue by region
Fiscal years, as SVA reports them in its 10-K filings; fiscal 2025 total $386M.
| Regions | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PRC | $71M | $173M | $215M | $227M | $366M | $10.9B | $1.1B | $403M | $297M | $261M | 68% |
| Outside Chinese Mainland | $1M | $1M | $15M | $19M | $145M | $8.5B | $399M | $67M | $64M | $125M | 32% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for SVA.
Open SVA in InvestinglyQuestions
Where does SVA make its money?
In fiscal 2019, by product: Enterovirus 71 vaccines $149M, Inactivated hepatitis vaccines $58M, Mumps Vaccines $20M, Influenza vaccines $19M.
From SVA's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.